Compare FSSL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSSL | VSTM |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 731.8M |
| IPO Year | 2025 | 2011 |
| Metric | FSSL | VSTM |
|---|---|---|
| Price | $11.57 | $9.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $17.22 |
| AVG Volume (30 Days) | 248.1K | ★ 4.7M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $260.03 |
| Revenue Next Year | N/A | $43.01 |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $10.75 | $3.43 |
| 52 Week High | $14.49 | $10.82 |
| Indicator | FSSL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 65.25 |
| Support Level | $11.31 | $5.41 |
| Resistance Level | $11.92 | N/A |
| Average True Range (ATR) | 0.23 | 0.89 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 45.69 | 89.77 |
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing mainly in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest mainly in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.